ReviewCurrent pharmaceutical design2020
Specificity and Continuity of Schizophrenia and Bipolar Disorder: Relation to Biomarkers.
Review in Current pharmaceutical design, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 10 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Transdiagnostic mapping of brain structural abnormalities and network-constrained gray matter atrophy patterns across affective and psychotic disorders.Molecular psychiatry · 2026Pooled it
- Comorbid Schizophrenia and Psychotic Symptoms in Patients With Bipolar Disorder: A Meta-Analysis of the Global Literature.Bipolar disorders · 2026Pooled it
- Transdiagnostic Neurocognitive Endophenotypes for Schizophrenia, Bipolar I Disorder and a Broad Psychosis/Bipolar I Disorder Phenotype: A Mega-Analysis of Twin and Sibling Data.Schizophrenia bulletin · 2026Pooled it
- Rethinking the psychosis spectrum: A meta-analysis unveils a nonlinear discontinuity in verbal learning deficits between at-risk conditions and psychotic disorders.European psychiatry : the journal of the Association of European Psychiatrists · 2025Pooled it
- Pharmaco-psychiatry and gut microbiome: a systematic review of effects of psychotropic drugs for bipolar disorder.Microbiology (Reading, England) · 2025Pooled it
- Quantitative analysis of literature on diagnostic biomarkers of Schizophrenia: revealing research hotspots and future prospects.BMC psychiatry · 2025Pooled it
- Psychotic relapse prediction via biomarker monitoring: a systematic review.Frontiers in psychiatry · 2024Pooled it
- Preclinical Evidence for the Mechanisms of Transcranial Direct Current Stimulation in the Treatment of Psychiatric Disorders; A Systematic Review.Clinical EEG and neuroscience · 2023Pooled it
- Emotion Recognition Deficits in Psychiatric Disorders as a Target of Non-invasive Neuromodulation: A Systematic Review.Clinical EEG and neuroscience · 2022Pooled it
- Retinal layers and associated clinical factors in schizophrenia spectrum disorders: a systematic review and meta-analysis.Molecular psychiatry · 2022Pooled it
- Probiotic Formulation for Patients With Bipolar or Schizophrenia Spectrum Disorder: A Double-Blind, Randomized Placebo-Controlled Trial.Schizophrenia bulletin · 2025Trial
- Cognitive decline in psychotic disorders: A longitudinal matched case-control study.Schizophrenia research. Cognition · 2026Article
- Prospective Volumetric Changes in the Thalamus in Adolescent First Episode of Mania and Cannabis Use: A Preliminary Study.Bipolar disorders · 2026Article
- Jumping to Conclusions in First-Episode Psychosis and Bipolar Disorder.Early intervention in psychiatry · 2026Article
- Influence of Sex and Diagnosis on Clinical Variables and Neurocognitive Performance in Severe Mental Illness. Results From the PsyCourse Study.Acta psychiatrica Scandinavica · 2026Article
- Joint effects of childhood adversity and genetic risk for psychosis on psychopathology in the UK Biobank.Psychological medicine · 2026Article
- Spatiotemporal complexity in the psychotic brain.Molecular psychiatry · 2026Article
- Does Administration of Low-Dose Aspirin Enhance the Efficacy of Psychotropic Drugs in Patients with Bipolar Disorder, Schizophrenia, and Schizoaffective Disorder?Pharmaceuticals (Basel, Switzerland) · 2026Article
- Genetic underpinnings of YMRS and MADRS scores variations in a bipolar sample.European archives of psychiatry and clinical neuroscience · 2026Article
- Differentiating Between Major Depressive Disorder and Bipolar Disorder.Advances in experimental medicine and biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia and bipolar disorder overlap considerably in terms of symptoms, familial patterns, risk genes, outcome, and treatment response. This article provides an overview of the specificity and continuity of schizophrenia and mood disorders on the basis of biomarkers, such as genes, molecules, cells, circuits, physiology and clinical phenomenology. Overall, the discussions herein provided support for the view that schizophrenia, schizoaffective disorder and bipolar disorder are in the continuum of severity of impairment, with bipolar disorder closer to normality and schizophrenia at the most severe end. This approach is based on the concept that examining biomarkers in several modalities across these diseases from the dimensional perspective would be meaningful. These considerations are expected to help develop new treatments for unmet needs, such as cognitive dysfunction, in psychiatric conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.